Please Wait.....
Report
Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032
Market Report I 2025-02-20 I 182 Pages I Market Research Future
Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032
Market Overview
It is anticipated that the Middle East and Africa Human Vaccine Market will experience a robust compound annual growth rate (CAGR) of 8.80% during the review period. The immune system is stimulated to produce immunity to a specific disease by biological preparations known as human vaccines, which protect individuals from infection and its potentially severe consequences. These vaccines typically contain attenuated or inactivated forms of pathogens (such as viruses or bacteria), their toxins, or surface proteins, which elicit an immune response without causing the disease.
The rise in disease burden and epidemic outbreaks, as well as the growing awareness of the significance of vaccination in the prevention of infectious diseases, are driving the expansion of the human vaccine market in the Middle East and Africa. In addition, the market will develop development opportunities in the future because of the growing funding and investment in expansion.
Market Segment Insights
The Middle East & Africa Human Vaccine Market has been segmented into the following categories: Inactivated, Toxoid, Conjugate and Subunit, and Recombinant DNA.This organization is based on the type of vaccine.
The Market has been segmented into Adults and Pediatrics based on age. The Pediatrics segment was the largest market in 2023 and the fastest-growing segment during the forecast period.
The Middle East & Africa Human Vaccine Market has been segmented into Pneumococcal, Influenza, Hepatitis, DTP, Polio, and other categories based on indication.
The Market has been segmented into Injectable, Oral, and Other based on the Route of Administration.
The market has been divided into Public and Private based on the distribution channel.
In 2023, the market was worth USD Egypt million. The Middle East is further divided into the following subregions: the United Arab Emirates (UAE), Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East.
The human vaccine market in the Middle East is poised for substantial development, because of the growing awareness of the significance of vaccination, rising healthcare expenditure, and heightened governmental support for vaccination. In April 2024, the Kingdom of Saudi Arabia committed $500 million over a five-year period to the Global Polio Eradication Initiative (GPEI). The market's expansion is additionally supported by the introduction of new vaccines that target a broader variety of diseases and advancements in vaccine technology. The current trends suggest a transition to personalized vaccines and a heightened investment in research and development to address the emergence of infectious diseases.
Major Players
Pfizer Inc, Vacsera, Merck & Co., Inc., AstraZeneca, SaudiVax, Cipla, GSK Plc, Sanofi, Biovac, Bharat Biotech, and AstraZeneca are the primary participants in the Middle East Human Vaccine Market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 20
2 MARKET INTRODUCTION 22
2.1 DEFINITION 22
2.2 SCOPE OF THE STUDY 22
2.3 RESEARCH OBJECTIVE 22
2.4 MARKET STRUCTURE 23
3 RESEARCH METHODOLOGY 24
3.1 OVERVIEW 24
3.2 DATA FLOW 26
3.2.1 DATA MINING PROCESS 26
3.3 PURCHASED DATABASE: 27
3.4 SECONDARY SOURCES: 28
3.4.1 SECONDARY RESEARCH DATA FLOW: 29
3.5 PRIMARY RESEARCH: 30
3.5.1 PRIMARY RESEARCH DATA FLOW: 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 32
3.6.1 REVENUE ANALYSIS APPROACH 32
3.7 DATA FORECASTING 33
3.7.1 DATA FORECASTING TYPE 33
3.8 DATA MODELING 34
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 34
3.8.2 DATA MODELING: 35
3.9 TEAMS AND ANALYST CONTRIBUTION 37
3.10 38
4 MARKET DYNAMICS 39
4.1 INTRODUCTION 39
4.2 DRIVERS 40
4.2.1 INCREASING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION IN PREVENTING INFECTIOUS DISEASES 40
4.2.2 RISING DISEASE BURDEN AND EPIDEMIC OUTBREAKS 40
4.2.3 RISING STRATEGIC INITIATIVES ASSOCIATED WITH VACCINE IN MIDDLE EAST & AFRICA 40
4.3 RESTRAINTS 41
4.3.1 STRINGENT REGULATORY POLICIES 41
4.4 OPPORTUNITY 43
4.4.1 INCREASING FUNDING AND INVESTMENT FOR EXPANSION 43
5 MARKET FACTOR ANALYSIS 44
5.1 PORTER'S FIVE FORCES MODEL 44
5.1.1 THREAT OF NEW ENTRANTS 45
5.1.2 BARGAINING POWER OF SUPPLIERS 45
5.1.3 BARGAINING POWER OF BUYERS 45
5.1.4 THREAT OF SUBSTITUTES 45
5.1.5 INTENSITY OF RIVALRY 45
5.2 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA HUMAN VACCINES MARKET 46
6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE 48
6.1 OVERVIEW 48
6.2 INACTIVATED 50
6.3 TOXOID 51
6.4 CONJUGATE AND SUBUNIT 51
6.5 RECOMBINANT DNA 51
7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP 52
7.1 OVERVIEW 52
7.2 PEDIATRICS 54
7.3 ADULTS 54
8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION 55
8.1 OVERVIEW 55
8.2 PNEUMOCOCCAL 58
8.3 INFLUENZA 58
8.4 HEPATITIS 58
8.4.1 HEPATITIS A 59
8.4.2 HEPATITIS B 60
8.5 DTP 60
8.6 POLIO 61
8.6.1 INACTIVATED POLIO VACCINE (IPV) 62
8.6.2 ORAL POLIO VACCINE (OPV) 62
8.7 HUMAN PAPILLOMAVIRUS 62
8.8 MENINGOCOCCAL 63
9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 64
9.1 OVERVIEW 64
9.2 INJECTABLE 67
9.3 ORAL 67
9.4 OTHERS 67
10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 68
10.1 OVERVIEW 68
10.2 PUBLIC 70
10.3 PRIVATE 70
11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION 71
11.1 MIDDLE EAST 72
11.1.1 UAE 79
11.1.2 SAUDI ARABIA 83
11.1.3 ISRAEL 87
11.1.4 KUWAIT 91
11.1.5 OMAN 96
11.1.6 QATAR 99
11.1.7 EGYPT 102
11.1.8 BAHRAIN 106
11.1.9 REST OF MIDDLE EAST 109
11.2 AFRICA 113
11.2.1 KENYA 119
11.2.2 SOUTH AFRICA 122
11.2.3 NIGERIA 126
11.2.4 MOZAMBIQUE 129
11.2.5 TANZANIA 132
11.2.6 UGANDA 136
11.2.7 MOROCCO 139
11.2.8 REST OF AFRICA 143
12 COMPETITIVE LANDSCAPE 148
12.1 INTRODUCTION 148
12.2 MARKET SHARE ANALYSIS, 2023 (%) 148
12.3 COMPETITOR DASHBOARD 149
12.4 PUBLIC PLAYERS STOCK SUMMARY 150
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 150
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 151
12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 151
12.6.2 AGREEMENT/COLLABORATION/PARTNERSHIP 151
13 COMPANY PROFILES 152
13.1 SANOFI 152
13.1.1 COMPANY OVERVIEW 152
13.1.2 FINANCIAL OVERVIEW 153
13.1.3 PRODUCTS OFFERED 153
13.1.4 KEY DEVELOPMENTS 154
13.1.5 SWOT ANALYSIS 155
13.1.6 KEY STRATEGIES 155
13.2 BHARAT BIOTECH 156
13.2.1 COMPANY OVERVIEW 156
13.2.2 FINANCIAL OVERVIEW 157
13.2.3 PRODUCTS OFFERED 157
13.2.4 KEY DEVELOPMENTS 157
13.2.5 KEY STRATEGIES 157
13.3 PFIZER INC 158
13.3.1 COMPANY OVERVIEW 158
13.3.2 FINANCIAL OVERVIEW 159
13.3.3 PRODUCTS OFFERED 159
13.3.4 KEY DEVELOPMENTS 160
13.3.5 SWOT ANALYSIS 160
13.3.6 KEY STRATEGIES 161
13.4 MERCK & CO., INC. 162
13.4.1 COMPANY OVERVIEW 162
13.4.2 FINANCIAL OVERVIEW 163
13.4.3 PRODUCTS OFFERED 164
13.4.4 KEY DEVELOPMENTS 164
13.4.5 KEY STRATEGIES 164
13.5 ASTRAZENECA 165
13.5.1 COMPANY OVERVIEW 165
13.5.2 FINANCIAL OVERVIEW 166
13.5.3 PRODUCTS OFFERED 166
13.5.4 KEY DEVELOPMENTS 167
13.5.5 KEY STRATEGIES 167
13.6 CIPLA 168
13.6.1 COMPANY OVERVIEW 168
13.6.2 FINANCIAL OVERVIEW 169
13.6.3 PRODUCTS OFFERED 169
13.6.4 KEY DEVELOPMENTS 169
13.6.5 SWOT ANALYSIS 170
13.6.6 KEY STRATEGIES 170
13.7 SAUDIVAX 171
13.7.1 COMPANY OVERVIEW 171
13.7.2 FINANCIAL OVERVIEW 172
13.7.3 PRODUCTS OFFERED 172
13.7.4 KEY DEVELOPMENTS 172
13.7.5 KEY STRATEGIES 172
13.8 GSK PLC 173
13.8.1 COMPANY OVERVIEW 173
13.8.2 FINANCIAL OVERVIEW 174
13.8.3 PRODUCT OFFERED 175
13.8.4 KEY DEVELOPMENTS 175
13.8.5 SWOT ANALYSIS 176
13.8.6 KEY STRATEGIES 176
13.9 BIOVAC 177
13.9.1 COMPANY OVERVIEW 177
13.9.2 FINANCIAL OVERVIEW 178
13.9.3 PRODUCTS OFFERED 178
13.9.4 KEY DEVELOPMENTS 178
13.9.5 KEY STRATEGIES 178
13.10 VACSERA 179
13.10.1 COMPANY OVERVIEW 179
13.10.2 FINANCIAL OVERVIEW 179
13.10.3 PRODUCTS OFFERED 179
13.10.4 KEY DEVELOPMENTS 180
13.10.5 KEY STRATEGIES 180
14 DATA CITATIONS 181
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35
TABLE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 49
TABLE 3 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 50
TABLE 4 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED, BY REGION, 2019-2032 (USD MILLION) 50
TABLE 5 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR TOXOID, BY REGION, 2019-2032 (USD MILLION) 51
TABLE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR CONJUGATE AND SUBUNIT, BY REGION, 2019-2032 (USD MILLION) 51
TABLE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR RECOMBINANT DNA, BY REGION, 2019-2032 (USD MILLION) 51
TABLE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 53
TABLE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PEDIATRICS, BY REGION, 2019-2032 (USD MILLION) 54
TABLE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ADULTS, BY REGION, 2019-2032 (USD MILLION) 54
TABLE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 56
TABLE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 57
TABLE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PNEUMOCOCCAL, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INFLUENZA, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 59
TABLE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 59
TABLE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS A, BY REGION, 2019-2032 (USD MILLION) 59
TABLE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS B, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR DTP, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY REGION, 2019-2032 (USD MILLION) 61
TABLE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 61
TABLE 23 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 61
TABLE 24 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED POLIO VACCINE (IPV), BY REGION, 2019-2032 (USD MILLION) 62
TABLE 25 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL POLIO VACCINE (OPV), BY REGION, 2019-2032 (USD MILLION) 62
TABLE 26 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2019-2032 (USD MILLION) 62
TABLE 27 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR MENINGOCOCCAL, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 28 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 65
TABLE 29 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INJECTABLE, BY REGION, 2019-2032 (USD MILLION) 67
TABLE 30 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL, BY REGION, 2019-2032 (USD MILLION) 67
TABLE 31 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION) 67
TABLE 32 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 69
TABLE 33 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PUBLIC, BY REGION, 2019-2032 (USD MILLION) 70
TABLE 34 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PRIVATE, BY REGION, 2019-2032 (USD MILLION) 70
TABLE 35 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2019-2032 (USD MILLION) 71
TABLE 36 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 74
TABLE 37 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION) 75
TABLE 38 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME) 76
TABLE 39 MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION) 76
TABLE 40 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION) 76
TABLE 41 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME) 77
TABLE 42 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION) 77
TABLE 43 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME) 77
TABLE 44 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION) 78
TABLE 45 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME) 78
TABLE 46 MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION) 78
TABLE 47 MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION) 79
TABLE 48 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION) 79
TABLE 49 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME) 79
TABLE 50 UAE: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION) 80
TABLE 51 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION) 80
TABLE 52 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME) 81
TABLE 53 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION) 81
TABLE 54 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME) 81
TABLE 55 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION) 82
TABLE 56 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME) 82
TABLE 57 UAE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION) 82
TABLE 58 UAE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION) 83
TABLE 59 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION) 83
TABLE 60 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME) 83
TABLE 61 SAUDI ARABIA: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION) 84
TABLE 62 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION) 84
TABLE 63 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME) 85
TABLE 64 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION) 85
TABLE 65 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME) 85
TABLE 66 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION) 86
TABLE 67 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME) 86
TABLE 68 SAUDI ARABIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION) 86
TABLE 69 SAUDI ARABIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION) 87
TABLE 70 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION) 87
TABLE 71 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME) 88
TABLE 72 ISRAEL: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION) 88
TABLE 73 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION) 88
TABLE 74 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME) 89
TABLE 75 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION) 89
TABLE 76 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME) 89
TABLE 77 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION) 90
TABLE 78 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME) 90
TABLE 79 ISRAEL: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION) 90
TABLE 80 ISRAEL: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION) 91
TABLE 81 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION) 91
TABLE 82 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME) 91
TABLE 83 KUWAIT: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION) 92
TABLE 84 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION) 92
TABLE 85 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME) 93
TABLE 86 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION) 93
TABLE 87 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME) 93
TABLE 88 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION) 94
TABLE 89 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME) 94
TABLE 90 KUWAIT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION) 94
TABLE 91 KUWAIT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION) 95
TABLE 92 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 96
TABLE 93 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 96
TABLE 94 OMAN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 96
TABLE 95 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 97
TABLE 96 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 97
TABLE 97 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 97
TABLE 98 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 98
TABLE 99 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 98
TABLE 100 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 98
TABLE 101 OMAN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 98
TABLE 102 OMAN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 99
TABLE 103 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 99
TABLE 104 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 99
TABLE 105 QATAR: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 100
TABLE 106 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 100
TABLE 107 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 100
TABLE 108 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 101
TABLE 109 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 101
TABLE 110 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 101
TABLE 111 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 101
TABLE 112 QATAR: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 102
TABLE 113 QATAR: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 102
TABLE 114 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 102
TABLE 115 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 103
TABLE 116 EGYPT: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 103
TABLE 117 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 103
TABLE 118 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 104
TABLE 119 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 104
TABLE 120 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 104
TABLE 121 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 105
TABLE 122 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 105
TABLE 123 EGYPT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 105
TABLE 124 EGYPT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 105
TABLE 125 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 106
TABLE 126 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 106
TABLE 127 BAHRAIN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 106
TABLE 128 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 107
TABLE 129 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 107
TABLE 130 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 107
TABLE 131 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 108
TABLE 132 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 108
TABLE 133 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 108
TABLE 134 BAHRAIN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 108
TABLE 135 BAHRAIN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 109
TABLE 136 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 109
TABLE 137 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 109
TABLE 138 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 110
TABLE 139 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 110
TABLE 140 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 110
TABLE 141 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 111
TABLE 142 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 111
TABLE 143 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 111
TABLE 144 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 111
TABLE 145 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 112
TABLE 146 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 112
TABLE 147 AFRICA: HUMAN VACCINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 115
TABLE 148 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 116
TABLE 149 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 116
TABLE 150 AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 116
TABLE 151 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 117
TABLE 152 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 117
TABLE 153 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 117
TABLE 154 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 118
TABLE 155 AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 118
TABLE 156 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 118
TABLE 157 AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 118
TABLE 158 AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 119
TABLE 159 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 119
TABLE 160 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 119
TABLE 161 KENYA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 120
TABLE 162 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 120
TABLE 163 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 120
TABLE 164 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 121
TABLE 165 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 121
TABLE 166 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 121
TABLE 167 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 121
TABLE 168 KENYA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 122
TABLE 169 KENYA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 122
TABLE 170 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 122
TABLE 171 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 123
TABLE 172 SOUTH AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 123
TABLE 173 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 123
TABLE 174 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 124
TABLE 175 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 124
TABLE 176 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 124
TABLE 177 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 125
TABLE 178 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 125
TABLE 179 SOUTH AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 125
TABLE 180 SOUTH AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 125
TABLE 181 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 126
TABLE 182 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 126
TABLE 183 NIGERIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 126
TABLE 184 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 127
TABLE 185 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 127
TABLE 186 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 127
TABLE 187 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 128
TABLE 188 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 128
TABLE 189 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 128
TABLE 190 NIGERIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 128
TABLE 191 NIGERIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 129
TABLE 192 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 129
TABLE 193 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 129
TABLE 194 MOZAMBIQUE: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 130
TABLE 195 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 130
TABLE 196 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 130
TABLE 197 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 131
TABLE 198 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 131
TABLE 199 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 131
TABLE 200 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 131
TABLE 201 MOZAMBIQUE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 132
TABLE 202 MOZAMBIQUE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 132
TABLE 203 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 132
TABLE 204 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 133
TABLE 205 TANZANIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 133
TABLE 206 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 133
TABLE 207 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 134
TABLE 208 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 134
TABLE 209 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 134
TABLE 210 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 135
TABLE 211 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 135
TABLE 212 TANZANIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 135
TABLE 213 TANZANIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 135
TABLE 214 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 136
TABLE 215 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 136
TABLE 216 UGANDA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 136
TABLE 217 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 137
TABLE 218 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 137
TABLE 219 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 137
TABLE 220 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 138
TABLE 221 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 138
TABLE 222 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 138
TABLE 223 UGANDA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 138
TABLE 224 UGANDA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 139
TABLE 225 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 139
TABLE 226 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 139
TABLE 227 MOROCCO: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 140
TABLE 228 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 140
TABLE 229 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 140
TABLE 230 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 141
TABLE 231 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 141
TABLE 232 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 141
TABLE 233 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 141
TABLE 234 MOROCCO: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 142
TABLE 235 MOROCCO: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 142
TABLE 236 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION) 143
TABLE 237 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME) 143
TABLE 238 REST OF AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION) 143
TABLE 239 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION) 144
TABLE 240 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME) 144
TABLE 241 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION) 144
TABLE 242 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME) 145
TABLE 243 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION) 145
TABLE 244 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME) 145
TABLE 245 REST OF AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION) 145
TABLE 246 REST OF AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION) 146
TABLE 247 PRODUCT LAUNCH/PRODUCT APPROVAL 151
TABLE 248 AGREEMENT/COLLABORATION/PARTNERSHIP 151
TABLE 249 SANOFI: PRODUCTS OFFERED 153
TABLE 250 SANOFI: KEY DEVELOPMENTS 154
TABLE 251 BHARAT BIOTECH: PRODUCT OFFERED 157
TABLE 252 BHARAT BIOTECH: KEY DEVELOPMENTS 157
TABLE 253 PFIZER INC: PRODUCT OFFERED 159
TABLE 254 PFIZER INC: KEY DEVELOPMENTS 160
TABLE 255 MERCK & CO., INC.: PRODUCTS OFFERED 164
TABLE 256 ASTRAZENECA: PRODUCT OFFERED 166
TABLE 257 CIPLA: PRODUCTS OFFERED 169
TABLE 258 SAUDIVAX: PRODUCTS OFFERED 172
TABLE 259 GSK PLC: PRODUCTS OFFERED 175
TABLE 260 GSK PLC: KEY DEVELOPMMENTS 175
TABLE 261 BIOVAC: PRODUCTS OFFERED 178
TABLE 262 VACSERA: PRODUCTS OFFERED 179
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: STRUCTURE 23
FIGURE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 39
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 41
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 42
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: MIDDLE EAST & AFRICA HUMAN VACCINE MARKET 44
FIGURE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, VACCINE TYPE SEGMENT, 2023 & 2032 (USD MILLION) 48
FIGURE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY TYPE, 2023 & 2032 (USD MILLION) 49
FIGURE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY VACCINE TYPE, 2023 50
FIGURE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, AGE-GROUP SEGMENT, 2023 & 2032 (USD MILLION) 52
FIGURE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION) 53
FIGURE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY AGE GROUP, 2023 54
FIGURE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, INDICATION SEGMENT, 2023 & 2032 (USD MILLION) 55
FIGURE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2023 & 2032 (USD MILLION) 56
FIGURE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY INDICATION, 2023 57
FIGURE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, ROUTE OF ADMINISTRATION SEGMENT, 2023 & 2032 (USD MILLION) 64
FIGURE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2032 (USD MILLION) 65
FIGURE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2023 66
FIGURE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, DISTRIBUTION CHANNEL SEGMENT, 2023 & 2032 (USD MILLION) 68
FIGURE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 69
FIGURE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 70
FIGURE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2023 & 2032 (USD MILLION) 71
FIGURE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE, BY REGION, 2023 (% SHARE) 72
FIGURE 23 MIDDLE EAST MARKET ANALYSIS: HUMAN VACCINE MARKET, 2019-2032 (USD MILLION) 73
FIGURE 24 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 74
FIGURE 25 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 (% SHARE) 75
FIGURE 26 AFRICA MARKET ANALYSIS: DIGITAL PCR MARKET, 2019-2032 (USD MILLION) 114
FIGURE 27 AFRICA HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 114
FIGURE 28 AFRICA HUMAN VACCINE MARKET SHARE, BY COUNTRY, 2023 (%) 115
FIGURE 29 MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 (%) 148
FIGURE 30 COMPETITOR DASHBOARD: MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET 149
FIGURE 31 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 32 SANOFI: SWOT ANALYSIS 155
FIGURE 33 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT 159
FIGURE 34 PFIZER INC: SWOT ANALYSIS 160
FIGURE 35 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 163
FIGURE 36 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 166
FIGURE 37 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 169
FIGURE 38 CIPLA: SWOT ANALYSIS 170
FIGURE 39 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT 174
FIGURE 40 GSK PLC: SWOT ANALYSIS 176
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security